Photocure $PHO trading above 50 and 200 SMA after Q2 report
Recent oversubscribed equity offerings done at 76 and 65,5 NOK after repurchasing global Hexvix ownership from Ipsen now securely in the money.
Recent newsflow:
13.08.2020 Photocure appoints Genotests as exclusive partner for Hexvix in Chile
08.07.2020 Photocure's partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira)
01.07.2020 Photocure appoints Susanne Strauss as Vice President and General Manager of Europe
24.06.2020 Private placement successfully placed - NOK 76
27.04.2020 Private placement successfully placed - NOK 65,5
27.04.2020 PHOTOCURE REGAINS WORLDWIDE RIGHTS OF HEXVIX
Recent newsflow:
13.08.2020 Photocure appoints Genotests as exclusive partner for Hexvix in Chile
08.07.2020 Photocure's partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira)
01.07.2020 Photocure appoints Susanne Strauss as Vice President and General Manager of Europe
24.06.2020 Private placement successfully placed - NOK 76
27.04.2020 Private placement successfully placed - NOK 65,5
27.04.2020 PHOTOCURE REGAINS WORLDWIDE RIGHTS OF HEXVIX
Verbundene Veröffentlichungen
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.